LRRK2-G2019S Synergizes with Ageing and Low-Grade Inflammation to Promote Gut and Peripheral Immune Cell Activation that Precede Nigrostriatal Degeneration

Output Details

Background Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most frequent cause of familial Parkinson’s disease (PD). The incomplete penetrance of LRRK2 mutations suggest that additional hits are required for disease onset. We hypothesized that chronic low-grade inflammation interacts with LRRK2 G2019S, the most frequent PD-associated mutation, to activate peripheral and central immune reactions and drive age-dependent neurodegeneration. Methods and Results We exposed wild-type and LRRK2 G2019S mice to a low chronic dose of lipopolysaccharide, and we performed a longitudinal analysis of central and peripheral immune reactions and neurodegeneration. Low-dose inflammation triggered nigrostriatal degeneration, macrophage/monocyte brain infiltration, and astro-/microgliosis. LRRK2 G2019S mice showed an early dysregulation of peripheral cytokines, increased CD4+ T-cell infiltration and α-synuclein aggregation in the colon. Interestingly, peripheral immune activation and colonic α-synuclein aggregation precede astro-/microgliosis and neurodegeneration. Conclusions Our study suggests an early role of the peripheral immune system and the gut in LRRK2 PD and provides a novel model to study early therapeutic immune targets and biomarkers.

Tags
  • Gut
  • Immune activation
  • Inflammation
  • LRRK2

Meet the Authors

  • User avatar fallback logo

    Carmela Giachino

  • User avatar fallback logo

    Cataldo Tirolo

  • User avatar fallback logo

    Salvatore Caniglia

  • User avatar fallback logo

    Maria F. Serapide

  • User avatar fallback logo

    Francesca L'Episcopo

  • Federico Bertoli, MD

    Key Personnel: Team Schapira

    German Center for Neurodegenerative Diseases

  • User avatar fallback logo

    Claudio Giuliano

  • User avatar fallback logo

    Marika Mearelli

  • User avatar fallback logo

    Meike Jakobi

  • User avatar fallback logo

    Nicole Schneiderhan-Marra

  • Michela Deleidi, MD, PhD

    Co-PI (Core Leadership): Team Schapira

    Institut Imagine

  • User avatar fallback logo

    Bianca Marchetti